Working… Menu

Radiation Therapy in Treating Women With Localized Breast Cancer (FAST)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00107497
Recruitment Status : Completed
First Posted : April 6, 2005
Last Update Posted : February 27, 2019
Information provided by (Responsible Party):
Institute of Cancer Research, United Kingdom

Brief Summary:

RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Giving radiation therapy in different ways and giving it after surgery may kill any tumor cells that remain after surgery.

PURPOSE: This randomized clinical trial is studying radiation therapy to see how well it works in treating women with localized breast cancer.

Condition or disease Intervention/treatment Phase
Breast Cancer Radiation: Radiation therapy Not Applicable

Detailed Description:


  • Compare late normal tissue effects of standard vs 2 different dose levels of hypofractionated adjuvant whole breast radiotherapy, in terms of changes in photographic breast appearance, in women with localized breast cancer who are at average or low risk of recurrence.
  • Compare tumor control in patients treated with these regimens.

OUTLINE: This is a randomized, multicenter study. Patients are stratified according to participating center. Patients are randomized to 1 of 3 treatment arms.

  • Arm I (control): Patients undergo standard radiotherapy 5 days a week for 5 weeks.
  • Arm II: Patients undergo hypofractional radiotherapy once a week for 5 weeks.
  • Arm III: Patients undergo hypofractional radiotherapy (at a lower dose than arm II) once a week for 5 weeks.

After completion of study treatment, patients are followed annually for 5-10 years.

PROJECTED ACCRUAL: A total of 900 patients (300 per treatment arm) will be accrued for this study within 12 months.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 917 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Prospective Randomised Clinical Trial Testing 5.7 Gy and 6.0 Gy Fractions of Whole Breast Radiotherapy in Terms of Late Normal Tissue Responses and Tumour Control - FAST
Actual Study Start Date : October 5, 2004
Actual Primary Completion Date : March 9, 2007
Actual Study Completion Date : March 9, 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Arm Intervention/treatment
Active Comparator: Control
50Gy in 25 fractions of radiation therapy over 5 weeks
Radiation: Radiation therapy
Active Comparator: Test group 1
30Gy in 5 fractions of radiation therapy over 5 weeks
Radiation: Radiation therapy
Active Comparator: Test group 2
28.5Gy in 5 fractions of radiation therapy over 5 weeks
Radiation: Radiation therapy

Primary Outcome Measures :
  1. Change in photographic breast appearance [ Time Frame: 2 years post randomisation ]
    Change in photographic breast appearance at 2 years post randomisation compared to a baseline pre-surgical photograph

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   50 Years to 120 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No


  • Diagnosis of invasive carcinoma of the breast

    • Localized disease

      • Pathological tumor size < 3.0 cm in diameter
      • Axillary node negative
  • At average or low risk of local tumor recurrence
  • Must have undergone prior breast-preserving surgery

    • No prior mastectomy
    • Complete microscopic resection of tumor
  • Hormone receptor status:

    • Not specified



  • 50 and over


  • Female

Menopausal status

  • Not specified

Performance status

  • Not specified

Life expectancy

  • Not specified


  • Not specified


  • Not specified


  • Not specified


  • Fertile patients must use effective contraception


Biologic therapy

  • Not specified


  • No prior neoadjuvant or adjuvant cytotoxic chemotherapy

Endocrine therapy

  • Not specified


  • No concurrent lymphatic radiotherapy
  • No concurrent radiotherapy boost to the breast


  • See Disease Characteristics

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00107497

Layout table for location information
United Kingdom
Sussex Cancer Centre at Royal Sussex County Hospital
Brighton, England, United Kingdom, BN2 5BE
Cumberland Infirmary
Carlisle, England, United Kingdom, CA2 7HY
Cheltenham General Hospital
Cheltenham, England, United Kingdom, GL53 7AN
Royal Devon and Exeter Hospital
Exeter, England, United Kingdom, EX2 5DW
Ipswich Hospital NHS Trust
Ipswich, England, United Kingdom, IP4 5PD
Christie Hospital NHS Trust
Manchester, England, United Kingdom, M20 4BX
Clatterbridge Centre for Oncology NHS Trust
Merseyside, England, United Kingdom, CH63 4JY
Berkshire Cancer Centre at Royal Berkshire Hospital
Reading, England, United Kingdom, RG1 5AN
Royal Shrewsbury Hospital
Shrewsbury, England, United Kingdom, SY3 8XQ
University Hospital of North Staffordshire
Stoke-On-Trent, England, United Kingdom, ST4 7LN
Royal Marsden NHS Foundation Trust - Surrey
Sutton, England, United Kingdom, SM2 5PT
Torbay Hospital
Torquay Devon, England, United Kingdom, TQ2 7AA
Royal Cornwall Hospital
Truro, Cornwall, England, United Kingdom, TR1 3LJ
Southend University Hospital NHS Foundation Trust
Westcliff-On-Sea, England, United Kingdom, SS0 0RY
Worcester Royal Hospital
Worcester, England, United Kingdom, WR5 1DD
Worthing Hospital
Worthing, England, United Kingdom, BN11 2DH
Velindre Cancer Center at Velindre Hospital
Cardiff, Wales, United Kingdom, CF14 2TL
Halton Hospital - North Cheshire Hospitals NHS Trust
Cheshire, United Kingdom, WA7 2DA
Hereford Hospitals NHS Trust
Hereford, United Kingdom, HR1 2ER
Sponsors and Collaborators
Institute of Cancer Research, United Kingdom
Layout table for investigator information
Study Chair: John R. Yarnold, MD, FRCR Royal Marsden NHS Foundation Trust

Additional Information:
Layout table for additonal information
Responsible Party: Institute of Cancer Research, United Kingdom Identifier: NCT00107497     History of Changes
Other Study ID Numbers: CDR0000417730
ICR-04/MRE06/17 ( Other Grant/Funding Number: UK MREC )
First Posted: April 6, 2005    Key Record Dates
Last Update Posted: February 27, 2019
Last Verified: February 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Institute of Cancer Research, United Kingdom:
stage I breast cancer
stage II breast cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases